What this means
The 2026 Barth Syndrome International Scientific, Medical & Family Conference was held at the Hyatt Regency Coconut Point, Bonita Springs, Florida, USA, from 19th to 25th July 2026 with scientific programming beginning 22nd July. S.
A plain-English summary is on its way. Until then, this is the start of the authors' own summary.
- Who it was tested in
- Not stated
- Kind of research
- A study
The science
- Original title
- Report from the 2026 Barth Syndrome Foundation International Scientific, Medical & Family Conference: Advances in Barth Syndrome Research, Therapy Development, and Clinical Care.
- Authors
- Marjoram L
- Journal
- Journal of developmental biology
- Published
- Oct 24, 2026
- Study type
- Study
- PMID
- 42924728 ↗
Abstract
The 2026 Barth Syndrome International Scientific, Medical & Family Conference was held at the Hyatt Regency Coconut Point, Bonita Springs, Florida, USA, from 19th to 25th July 2026 with scientific programming beginning 22nd July. This biennial event assembled researchers, clinicians, and affected community members for its first gathering since the U.S. FDA granted accelerated approval to elamipretide (Forzinity™; Mighty Therapeutics), the first therapy for Barth syndrome and first ever mitochondrially targeted therapy, in September 2025. Scientific sessions addressed: (1) emerging cardiolipin biology; (2) convergent identification of ABHD18 as a therapeutic target for correction of the cardiolipin phenotype; (3) advancing therapeutic strategies including AAV gene therapy, enzyme replacement therapy, and ABHD18 inhibition; (4) the elamipretide post-approval program, including the SPIBA-401 confirmatory trial; (5) natural history characterization covering infant outcomes, extra-cardiac manifestations, diaphragm weakness, neutropenia, and amino acid metabolism; (6) regulatory and drug development strategies in ultra-rare indications; and (7) international Centers of Expertise models and the launch of the BarthINSIGHTS registry. This report summarizes the key scientific advances, discussions, and future priorities as they relate to Barth syndrome biology, therapeutic development, and clinical care.
Marjoram L Report from the 2026 Barth Syndrome Foundation International Scientific, Medical & Family Conference: Advances in Barth Syndrome Research, Therapy Development, and Clinical Care. Journal of developmental biology. 2026. doi:10.3390/jdb14040045. PMID: 42924728. https://pubmed.ncbi.nlm.nih.gov/42924728/
Related research
The Role of Oxidative Stress in Heart Failure: Mechanisms and Therapeutic Targets.
Heart failure is characterised by increased production of reactive oxygen species (ROS), which contribute to apoptotic signalling.
A peptide eased signs of aging in heart cells damaged by a cancer drug
Researchers treated heart muscle cells in a dish with a cancer drug, then a peptide called SS-31. The peptide reduced several signs of aging, but not cell cycle arrest. This was done only in lab cells, so it does not show the peptide would help people.
Two drugs together eased stroke brain damage in mice
Researchers gave mice two compounds, alone and together, after a stroke-like injury to the brain. The mice given both had less brain damage and better nerve function than those given either one alone.
Peptide SS-31 eased radiation-caused aging signs in heart cells
Researchers exposed heart cells to radiation and gave some of them SS-31. SS-31 reduced several aging signs, but this was only tested in cells, not people.
Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics.
Postoperative cognitive dysfunction (POCD) is a frequent neurological complication in older surgical patients, leading to substantial declines in quality of life and placing a considerable burden on society.
Two mitochondria-targeted drugs studied in aged female mice with fatty liver disease
Researchers gave two drugs to older mice with fatty liver disease caused by a rich diet. Both drugs improved liver markers in the mice, but this does not show they would help people.
See all research on Elamipretide (SS-31) →